SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Honghong, Zhou, Baoqin, Xu, Gaosi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434580/
https://www.ncbi.nlm.nih.gov/pubmed/28511711
http://dx.doi.org/10.1186/s12933-017-0547-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434580/
https://www.ncbi.nlm.nih.gov/pubmed/28511711
http://dx.doi.org/10.1186/s12933-017-0547-1

Ejemplares similares